| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
CDK6 4.4 nM (IC50)
|
|---|---|
| ln Vitro |
In Ph+ BV173 and SUP-B15 cells, YX-2-107 (2000 nM; 48 h) inhibits the S phase[1]. CDK6 in BV173 cells is selectively degraded by YX-2-107 (0, 1.6, 8, 40, 200, and 1000 nM; 4 h)[1]. Ph+ BV173 and SUP-B15 cells' RB phosphorylation and FOXM1 expression are inhibited by YX-2-107 (2000 nM; 72 h)[1].
|
| ln Vivo |
After 4 hours, YX-2-107 (10 mg/kg; ip; single) is cleared from the plasma at a maximum concentration of 741 nM, which is 150 times higher than the CDK6 degradation IC50[1]. Pharmacologically, YX-2-107 (150 mg/kg; ip; once daily for three days) inhibits the growth of Ph+ ALL in mice[1].
|
| Cell Assay |
Cell Cycle Analysis[1]
Cell Types: Ph+ BV173 and SUP-B15 cells Tested Concentrations: 2000 nM Incubation Duration: 48 h Experimental Results: Inhibited S-phase entry. Western Blot Analysis[1] Cell Types: Ph+ BV173 and SUP-B15 cells Tested Concentrations: 2000 nM Incubation Duration: 72 h Experimental Results: Inhibited the phosphorylation of RB and the expression of FOXM1. |
| Animal Protocol |
Animal/Disease Models: NRG- SGM3 mice (Ph+ ALL xenografts model)[1].
Doses: 150 mg/kg Route of Administration: intraperitoneal (ip)injection; single daily for 3 days Experimental Results: Suppressed the percentage of primary Ph+ ALL S-phase cells, the expression of CDK4/6-regulated phospho-RB and, to a lesser degree, FOXM1, and induced the selective CDK6 degradation. Animal/Disease Models: C57BL/6j mice[1]. Doses: 10 mg/kg Route of Administration: intraperitoneal (ip)injection; single Experimental Results: 1.19 pharmacokinetic/PK Parameters of YX- 2-107 in C57BL/6j mice [1]. IP (10 mg/kg) Tmax (h) 0.5 Cmax (ng/mL) 660 AUC0-t (ng/mL·h) 815 AUC0-∞ (ng/mL· h) 987 |
| References |
[1]. De Dominici M, et al. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs. Blood. 2020 Apr 30;135(18):1560-1573.
|
| Molecular Formula |
C45H51N11O9
|
|---|---|
| Molecular Weight |
889.95
|
| Exact Mass |
889.39
|
| Elemental Analysis |
C, 60.73; H, 5.78; N, 17.31; O, 16.18
|
| CAS # |
2417408-46-7
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
O=C1NC(C(CC1)N2C(C3=C(C2=O)C(OCC(NCCCCNCC(N4CCN(CC4)C5=CN=C(NC6=NC(N(C7CCCC7)C(C(C(C)=O)=C8C)=O)=C8C=N6)C=C5)=O)=O)=CC=C3)=O)=O
|
| InChi Key |
JNYCZFGLJGFFEL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C45H51N11O9/c1-26-31-23-49-45(52-40(31)55(28-8-3-4-9-28)43(63)38(26)27(2)57)50-34-14-12-29(22-48-34)53-18-20-54(21-19-53)37(60)24-46-16-5-6-17-47-36(59)25-65-33-11-7-10-30-39(33)44(64)56(42(30)62)32-13-15-35(58)51-41(32)61/h7,10-12,14,22-23,28,32,46H,3-6,8-9,13,15-21,24-25H2,1-2H3,(H,47,59)(H,51,58,61)(H,48,49,50,52)
|
| Chemical Name |
N-(4-((2-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-2-oxoethyl)amino)butyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide
|
| Synonyms |
YX-2-107; SCHEMBL24172331; CS-0634381
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (112.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1237 mL | 5.6183 mL | 11.2366 mL | |
| 5 mM | 0.2247 mL | 1.1237 mL | 2.2473 mL | |
| 10 mM | 0.1124 mL | 0.5618 mL | 1.1237 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
